Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape

Drug Delivery

Volumn 23, Issue 9, 2016, Pages 3319-3329

  Zylberberg, Claudia ^a   Matosevic, Sandro ^a  

^a Akron Biotech   (United States)

Author keywords

Bioengineering; drug delivery; liposomes; regulatory landscape; synthetic biology

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETHOSOME; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIPOSOME; MORPHINE SULFATE; PHARMACOSOME; TRANSFEROSOME; UNCLASSIFIED DRUG; VERTEPORFIN; VINCRISTINE SULFATE; DRUG CARRIER;

CELL ORGANELLE; CIRCULATION TIME; DRUG SOLUBILITY; ELASTICITY; LIPID COMPOSITION; LIPOSOMAL DELIVERY; NEBULIZATION; PRIORITY JOURNAL; REVIEW; SKIN PENETRATION; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; PROCEDURES;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES;

EID: 84965021006     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717544.2016.1177136     Document Type: Review

References (90)

1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI., (2002). Targeting to macrophages:role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release 79:29–40
2. Alemdaroğlu C, Degim Z, Celebi N, et al. (2008). Investigation of epidermal growth factor containing liposome formulation effects on burn wound healing. J Biomed Mater Res A 85:271–83
3. Allen TM, Brandeis E, Hansen CB, et al. (1995). A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237:99–108
4. Allena MT, Cullis PR., (2013). Liposomal drug delivery systems:from concept to clinical applications. Adv Drug Deliv Rev 65:36–48
5. Andresen TL, Jensen SS, Jorgensen K., (2005). Advanced strategies in liposomal cancer therapy:problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97
6. Bangham AD, Standish MM, Watkins JC., (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–52
7. Bendas ER, Tadros MI., (2007). Enhanced transdermal delivery of salbutamol sulfate via ethosomes. AAPS PharmSciTech 8:213–20
8. Bibi S, Lattmann E, Mohammed AR, Perrie Y., (2012). Trigger release liposome systems:local and remote controlled delivery. J Microencapsul 29:262–76
9. Biswas S, Dodwadkar NS, Sawant RR, et al. (2011). Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting. J Drug Target 19:552–61
10. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS., (2003). Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 42:1–36
11. Bragagni M, Mennini N, Maestrelli F, et al. (2012). Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv 19:354–61
12. Byrne JD, Betancourt T, Brannon-Peppas L., (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–26
13. Chandel A, Vishal Patil V, Goyal R, et al. (2012). Ethosomes:a novel approach towards transdermal drug delivery. Int J Pharm Chem Sci 1:563–9
14. Chang DK, Lin CT, Wu CH, Wu HC., (2009). A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4:e4171
15. Chang HI, Yeh MK., (2012). Clinical development of liposome-based drugs:formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49–60
16. Chatap VK, Patil PL, Patil SD., (2014). In-vitro, ex-vivo characterization of furosemide bounded pharmacosomes for improvement of solubility and permeability. Adv Pharmacol Pharm 2:67–76
17. Darwhekar G, Kumar Jain D, Choudhary A., (2012). Elastic liposomes for delivery of neomycin sulphate in deep skin infection. Asian J Pharm Sci 7:230–40
18. Deepthi V, Kavitha A. (2014). Liposomal drug delivery system:a review. RGUHS J Pharm Sci 4:47–56
19. Duangjita S, Opanasopitb P, Rojanaratac T, Ngawhirunpatd T., (2011). Effect of edge activator on characteristic and in vitro skin permeation of meloxicam loaded in elastic liposomes. Adv Mater Res 194-196:537–40
20. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM., (2007). Lipid vesicles for skin delivery of drugs:reviewing three decades of research. Int J Pharma 332:1–16
21. European Medicines Agency. (2011). Draft reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109479.pdf [last accessed 2 May 2013]
22. European Medicines Agency. (2009). Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework. Available at:http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004011.pdf [last accessed 2 May 2013]
23. Fahr A, van Hoogevest P, May S, et al. (2005). Transfer of lipophilic drugs between liposomal membranes and biological interfaces:consequences for drug delivery. Eur J Pharm Sci 26:251–65
24. Fan C, Li X, Zhou Y, et al. (2013). Enhanced topical delivery of tetrandrine by ethosomes for treatment of arthritis. BioMed Res Int 2013:161943. doi:http://dx.doi.org/12010/2013/161943
25. Federman N, Denny CT., (2010). Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr Res 67:514–19
26. Feldman EJ, Kolitz JE, Trang JM., (2012). Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res 36:1283–9
27. Gabizon A, Horowitz AT, Goren D, et al. (2003). In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9:6551–9
28. Ghannouma M, Ishama N, Henryb W, et al. (2012). Evaluation of the morphological effects of TDT 067 (terbinafine in transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo. Antimicrob Agents Chemother 56:2530–4
29. Hua S, Wu SY., (2013). The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol 4:143. doi:10.3389/fphar.2013.00143
30. Irfan M, Verma S, Ram A., (2012). Preparation and characterization of ibuprofen loaded transferosome as a novel carrier for transdermal drug delivery system. Asian J Pharm Clin Res 5:162–5
31. Isayed MM, Abdallah OY, Naggar VF, Khalafallah NM., (2006). Deformable liposomes and ethosomes:mechanism of enhanced skin delivery. Int J Pharm 322:60–6
32. Kalbitz J, Neubert R, Wohlrab W., (1996). Modulation of drug penetration in the skin. Pharmazie 51:619–37
33. Kamalesh M, Diraj DB, Kiran B, Wagh K., (2014). Formulation and evaluation of pharmacosomes of ketoprofen. IAJPR 4:1363–8
34. Karande P, Mitragotri S., (2009). Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim Biophys Acta:Biomembranes 1788:2362–73
35. Karmali PP, Chaudhuri A., (2007). Cationic liposomes as non-viral carriers of gene medicines:resolved issues, open questions, and future promises. Med Res Rev 27:696–722
36. Kneer W, Rother M, Mazgareanu S, et al. (2013). A 12-week randomized study of topical therapy with three dosages of ketoprofen in Transfersome® gel (IDEA-033) compared with the ketoprofen-free vehicle (TDT 064), in patients with osteoarthritis of the knee. J Pain Res 6:743–53
37. Koshkina NV, Gilbert BE, Waldrep JC, et al. (1999). Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 44:187–92
38. Lachenmeier DW., (2008). Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity. J Occup Med Toxicol 3:26. doi:10.1186/1745-6673-3-26
39. Langer R., (2004). Transdermal drug delivery:past progress, current status, and future prospects. Adv Drug Deliv Rev 56:557–8
40. Lee EH, Kim A, Kim CK., (2005). Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials 26:205–10
41. Lee JS, Ankone M, Pieters E, et al. (2011). Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice:comparison with stealth liposomes. J Control Release 155:282–8
42. Lemière J, Carvalho K, Sykes C., (2015). Cell-sized liposomes that mimic cell motility and the cell cortex. Methods Cell Biol 128:271–85
43. Li Z, Zhang Y, Wurtz W, et al. (2008). Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 21:245–54
44. Liechty WB, Peppas NA., (2012). Expert opinion:responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm 80:241–6
45. Lu K, Xie S, Han S, et al. (2014). Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats. J Transl Med 12:72. doi:10.1186/1479-5876-12-72
46. Madeira C, Mendes RD, Ribeiro SC, et al. (2010). Nonviral gene delivery to mesenchymal stem cells using cationic liposomes for gene and cell therapy. J Biomed Biotechnol 2010:735349. doi:http://dx.doi.org/12010/2010/735349
47. Matosevic S, Paegel B., (2013). Layer-by-layer cell membrane assembly. Nat Chem 5:958–63
48. Matosevic S., (2012). Synthesizing artificial cells from giant unilamellar vesicles:state-of-the art in the development of microfluidic technology. Bioessays 34:992–1001
49. Meerovich I, Koshkaryev A, Thekkedath R, Torchilin VP., (2011). Screening and optimization of ligand conjugates for lysosomal targeting. Bioconjug Chem 22:2271–82
50. Meng S, Chen Z, Yang L, et al. (2013). Enhanced transdermal bioavailability of testosterone propionate via surfactant-modified ethosomes. Int J Nanomed 8:3051–60
51. Mohammed A, Weston N, Coombes A, et al. (2005). Liposome formulation of poorly water soluble drugs:optimisation of drug loading and ESEM analysis of stability. Int J Pharm 285:23–34
52. Mouritsen O., (2011). Lipids, curvature, and nano-medicine. Eur J Lipid Sci Technol 113:1174–87
53. Nag OK, Awasthi V., (2013). Surface engineering of liposomes for stealth behavior. Pharmaceutics 5:542–69
54. Nakanishi T, Aoki D, Watanabe Y, et al. (2015). A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. Jpn J Clin Oncol 45:422–6
55. Parhi P, Mohanty C, Sahoo SK., (2012). Nanotechnology-based combinational drug delivery:an emerging approach for cancer therapy. Drug Discov Today 17:1044–52
56. Park JW., (2002). Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4:95–9
57. Pasut G, Paolino D, Celia C, et al. (2003). Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J Control Release 199:106–13
58. Pinheiro M, Lúcio M., (2011). Liposomes as drug delivery systems for the treatment of TB. Nanomedicine (Lond) 6:1413–28
59. Puri A., (2014). Phototriggerable liposomes:current research and future perspectives. Pharmaceutics 6:1–25
60. Reuters. (2011). Available at:http://www.reuters.com/article/2011/07/21/us-johnsonandjohnson-doxil-idUSTRE76K70E20110721 [last accessed 28 June 2015]
61. Rogers JA, Anderson KE., (1998). The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carrier Syst 15:421–80
62. Sakurai Y, Kajimoto K, Harashima H., (2015). Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature. Biomater Sci 3:1253–65
63. Samad A, Sultana Y, Aqil M., (2007). Liposomal drug delivery systems:an update review. Curr Drug Deliv 4:297–305
64. Sawant RR, Torchilin VP., (2012). Challenges in development of targeted liposomal therapeutics. AAPS J 14:303–15
65. Semalty A, Semalty M, Rawat BS, et al. (2009). Pharmacosomes:the lipid-based new drug delivery system. Exp Opin Drug Deliv 6:599–612
66. Semalty A, Semalty M, Rawat BS, et al. (2010). Development and evaluation of pharmacosomes of aceclofenac. Indian J Pharm Sci 72:576–81
67. Sercombe L, Veerati T, Moheimani F, et al. (2015). Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286
68. Shaikh IM, Tan KB, Chaudhury A, et al. (2013). Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. J Control Release. [Epub ahead of print]. doi:10.1016/j.jconrel.2013.10.025
69. Sharma PH, Powar PV, Sharma SS., (2014). Pharmacosomes:a novel drug delivery system. Pharma Innov J 3:94–100
70. Sharma VK, Sarwa KK, Mazumder B., (2014). Fluidity enhancement:a critical factor for performance of liposomal transdermal drug delivery system. J Liposome Res 24:83–9
71. Shivhare R, Pathak A, Shrivastava N, et al. (2013). An update review on novel advanced ocular drug delivery system. World J Pharm Pharmaceut Sci 1:545–68
72. Sun GY, Sun AY., (1985). Ethanol and membrane lipids. Alcohol Clin Exp Res 9:164–80
73. Tang Y, Gan X, Cheheltani R, et al. (2014). Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model. Nanomedicine 10:1711–18
74. Torchilin VP., (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9:128–47
75. Torchilin VP., (2010). Passive and active drug targeting:drug delivery to tumors as an example. Handb Exp Pharmacol 197:3–53
76. Touitou E, Alkabes M, Dayan Eliaz M., (1997). Ethosomes:novel vesicular carriers for enhanced skin delivery. Pharm Res 14:S305–6
77. Touitou E, Dayan N, Bergelson L, et al. (2000). Ethosomes-novel vesicular carriers for enhanced delivery:characterization and skin penetration properties. J Control Release 65:403–18
78. Tseng WC, Huang L., (1998). Liposome-based gene therapy. Pharm Sci Tech Today 1:206–13
79. US Food and Drug Administration. (2014). Draft guidance on doxorubicin hydrochloride. Available at:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf [last accessed 2 May 2013]
80. Van Slooten ML, Boerman O, Romøren K, et al. (2001). Liposomes as sustained release system for human interferon-gamma:biopharmaceutical aspects. Biochim Biophys Acta 1530:134–45
81. Verma P, Pathak K., (2010). Therapeutic and cosmeceutical potential of ethosomes:an overview. J Adv Pharm Technol Res 1:274–82
82. Vujaskovic Z, Kim DW, Jones E, et al. (2010). A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 26:514–21
83. Wang Y, Su HH, Yang Y, et al. (2013). Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 21:358–67
84. Watkinson AC, Bunge AL, Hadgraft J, Lane ME., (2013). Nanoparticles do not penetrate human skin-a theoretical perspective. Pharm Res 30:1943–6
85. Willis MC, Collins BD, Zhang T, et al. (1998). Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 9:573–82
86. Xu DH, Zhang Q, Feng X, et al. (2007). Synergistic effects of ethosomes and chemical enhancers on enhancement of naloxone permeation through human skin. Pharmazie 62:316–18
87. Yudina A, de Smet M, Lepetit-Coiffé M, et al. (2011). Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. J Control Release 155:442–8
88. Zalipsky S, Qazen M, Walker IIJA, et al. (1999). New detachable poly(ethylene glycol) conjugates:cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 10:703–7
89. Zheng C, Ma C, Bai E, et al. (2015). Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. Int J Clin Exp Med 8:1658–68
90. Zhu L, Kate P, Torchilin VP., (2012). Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 6:3491–8